Searchable abstracts of presentations at key conferences in endocrinology

ea0029p328 | Cardiovascular Endocrinology and Lipid Metabolism | ICEECE2012

Effect of medical therapy on 24-h blood pressure profile in acromegaly

Sardella C. , Nuzzo A. , Urbani C. , Lombardi M. , Scattina I. , Tomisti L. , Martino E. , Bogazzi F.

To investigate the blood pressure profile (BP) in active acromegaly and the effect of medical treatment of acromegaly on BP circadian rhythm, we studied 21 acromegalics before and after 3–60 months of treatment with somatostatin analogs (15/21) or pegvisomant (5/21) or both (5/21). Ambulatory 24-h BP was recorded. The 24-h mean BP (MBP), the mean systolic BP (SBP) and diastolic BP (DBP), the day-time (day) and night-time (night) MBP, SBP and DBP and the 24-h mean heart ra...

ea0029p1398 | Pituitary Clinical | ICEECE2012

Effects of medical therapy of acromegaly on glucose metabolism

Urbani C. , Calevro A. , Scattina I. , Lombardi M. , Sardella C. , Nuzzo A. , Marchello A. , Martino E. , Bogazzi F.

Introduction: Acromegaly is associated with alterations of glucose metabolism. The effect of somatostatin analogues (SMS) and pegvisomant (PEG) on glucose metabolism is still argument of debate.Study design: The purpose of this historical-prospective study was to compare, in a cohort of 47 patients with active acromegaly, the effects of SMS and PEG alone or in combination on glucose metabolism. All subjects were evaluated at baseline and at least 6 month...

ea0029p1455 | Pituitary Clinical | ICEECE2012

Glucose metabolism in children with GH deficiency before and after GH therapy

De Martino L. , Capalbo D. , Di Mase R. , Esposito A. , Rezzuto M. , Barbieri F. , Salerno M.

Background: Adults with untreated GH deficiency (GHD) may have a cluster of cardiovascular risk factors. The effects of GH replacement therapy on insulin homeostasis in GHD subjects are still debated. Only a few studies investigated the effects of GHD and GH therapy on glucose metabolism in children.Objective: To evaluate the effects of GHD and GH treatment on glucose metabolism in a large cohort of GHD children before and after GH replacement therapy.</...

ea0029p1465 | Pituitary Clinical | ICEECE2012

Colonic neoplasms in acromegaly: are there serum risk factors?

Lombardi M , Scattina I , Urbani C , Sardella C , Marchello A , Nuzzo A , Dell'Unto E , Martino E , Bogazzi F

Hyperinsulinemia has been associated to an increased risk of colorectal cancer and adenomas, while higher serum 25-hydroxy vitamin D3 and folate seem to reduce the development of colonic lesions in general population. Acromegalic patients have an increased risk of colonic tumors and an association between higher fasting insulin levels and risk of colonic adenomas has been previously demonstrated. No data are available about the influence of vitamin D and folate-homocysteine le...

ea0022p5 | Adrenal | ECE2010

Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome: a longitudinal study

Raffaelli Valentina , Manetti Luca , Ruocco Lucia , Giovannetti Clara , Genovesi Maura , Pellegrini Giovanni , Bogazzi Fausto , Martino Enio

Patients with active Cushing’s syndrome (CS) have an increased coagulability and thrombotic tendency. High glucocorticoids concentrations increase plasma clotting factors, especially von Willebrand factor (vWf) and reduced fibrinolytic capacity. Thromboemobolic complications, mainly in the postsurgical phase, have been reported.Aim of this longitudinal study was to evaluate haemostatic and fibrinolytic markers in patients with active Cushing’s ...

ea0022p564 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Use of cabergolin in Nelson's syndrome: preliminary results in four patients

Giovannetti Clara , Manetti Luca , Raffaelli Valentina , Cosottini Mirco , Genovesi Maura , Martino Enio

The Nelson’s syndrome (NS) is characterized by hyperpigmentation, sellar growing mass, and increased plasma ACTH concentrations The management of NS remains difficult: neurosurgery represent the first choice therapy. Many drugs have been used with variable results: cyproeptadine, GABA-agonists, somatostatin analogues, chemiotherapy, PPAR-γ-agonists, and dopamin-agonists.Aim of this study was to evaluate the efficacy of cabergoline administratio...

ea0022p606 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Impact of rosiglitazone on serum IGF1 concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study

Lombardi Martina , Rossi Giuseppe , Raggi Francesco , Urbani Claudio , Sardella Chiara , Cosci Chiara , Martino Enio , Bogazzi Fausto

Current therapies for acromegaly are unsatisfactory for some patients. High dose thiazoledinedines have been reported to shrink tumor size and reduce serum GH levels in animal models of acromegaly. To study the effects of increasing doses of rosiglitazone on serum GH and IGF1 concentrations in acromegalic patients, we designed a phase two clinical trial. We enrolled five consecutive patients with active acromegaly uncontrolled under conventional therapies. They received increa...

ea0022p613 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma

Lupi Isabella , Manetti Luca , Caturegli Patrizio , Menicagli Michele , Bevilacqua Genersoso , Bogazzi Fausto , Martino Enio

Serum pituitary antibodies (Pit Abs) and tumor infiltrating lymphocytes (TILs) have been described in a small percentage of pituitary adenomas but their clinical significance remains unknown.Aim of the study was to assess Pit Abs and TILs prevalence in patients with pituitary adenomas and to determine their influence on the clinical outcome. In this prevalence case–control study were enrolled 291 pituitary adenoma cases, (110 non-secreting, 30 ACTH-...

ea0022p765 | Thyroid | ECE2010

Amiodarone-induced thyrotoxicosis in patients with multinodular goiter: type 1 or type 2 AIT?

Tomisti Luca , Dell'Unto Enrica , Brogioni Sandra , Cosci Chiara , Martino Enio , Bogazzi Fausto

Introduction: Type 2 amiodarone-induced thyrotoxicosis (AIT) is a form of destructive thyroiditis, commonly responsive to glucocorticoids. On the contrary, type 1 AIT is an iodine-induced hyperthyroidism, occurring in patients with underlying thyroid disease often responding to thionamides.Aim of the study: To compare the effectiveness of methimazole (MMI) or prednisone (GLU) in the treatment of AIT patients with multinodular goiter with biochemical feat...

ea0020s4.2 | Gonadal steroid replacement | ECE2009

Pharmacogenetics of androgen action

Canale D , Caglieresi C , Gavioli S , Moscatelli A , Martino E , Vitti P

Hypogonadism is still a poorly-defined clinical entity. Recently approved and published guidelines to diagnosis and treatment of hypogonadism claim the necessity of accompanying biochemical thresholds with clinical symptoms and monitoring under treatment a specific aspect of the ‘wide spectrum’ hypogonadism (libido, erection, bone mass, muscle strength and so on). This is due both to different levels of thresholds for different tissues and to individual variability.<...